Board of Directors
Elizabeth Douville, Ph.D, AmorChem Venture Fund & Chairman of the Board SemaThera Inc.
Elizabeth Douville is the Founder and Managing Partner of AmorChem Venture Fund, a Québec-based seed venture fund dedicated to financing and commercializing university technologies. Dr. Douville brings to AmorChem a deep and longstanding experience in venture capital investing having been General Partner of GeneChem, a leading North American life sciences venture capital fund manager from 1997 to 2011. Dr. Douville is very involved and active in the life sciences industry, providing guidance and leadership to federal and provincial granting agencies. Dr. Douville obtained her Ph.D. in biochemistry from the University of Ottawa under the direction of Dr. John Bell and did her postdoctoral training under the guidance of Dr. Julian Downward at the Imperial Cancer Research Fund in London. In 2008, Dr. Douville obtained a business degree as part an Executive management and training program offered by CIREM in collaboration with HEC/University of Montreal.
Tomio Kikuya, Senju Pharmaceutical Co., Ltd.
M. Tomio Kikuya is Director, New Business Creation and Development of Senju Pharmaceutical Co. Ltd. He joined Senju in 1992 and worked in different positions in Licensing, International Business, Los Angeles Office, Amsterdam Office, Business Development, and Corporate Planning before taking on his current role.
Garth Cumberlidge, PhD, SemaThera Inc.
Garth is the President & Chief Executive Officer of SemaThera. Additionally, he is chairman of the Board of Directors of Eyevensys, a French biotechnology company developing novel non-viral gene therapy platform for visionthreatening ocular diseases. He is the former President and Chief Executive Officer of Mimetogen Pharmaceuticals Inc., a biotechnology company developing novel neuroprotective and neurostimulatory compounds for the treatment of ocular diseases. Prior to Mimetogen, Dr. Cumberlidge served as President & CEO of Qbiogene Inc., a company providing life sciences research products and custom cGMP manufacturing services to academic, biotechnology and pharmaceutical researchers worldwide. Dr. Cumberlidge holds degrees in Biochemistry and Genetics from the University of London (U.K.) and in Molecular Genetics from the Max-Planck-Institute for Molecular Genetics, Berlin (Germany).
Andreas Stahl, MD, Klinik fuer Augenheilkunde, Universitaetsmedizin, Greifswald.
Prof. Dr. Andreas Stahl began his clinical career at the Freiburg University Eye Clinic. Research residencies in 2004 and 2008 – 2010 at Harvard Medical School, Boston (USA). Since 2014, he has headed the Department of Outpatient Retinal Surgery in Freiburg. His medical focus lies in the entire spectrum of conservative and operative retinology. Prof. Stahl is the author of numerous specialist publications and clinical therapy studies as well as a member of the Executive Board of the German Retinological Society. He is also a guideline officer for the screening and treatment of retinopathy of prematurity.